IQVIA Holdings Inc. $IQV Shares Acquired by GDS Wealth Management

Key Points

• GDS Wealth Management increased its stake in IQVIA Holdings Inc. by 11.7%, acquiring a total of 66,471 shares valued at approximately $11.7 million.
• Several institutional investors, including Clal Insurance and Golden State Wealth Management, have also made significant changes to their positions in IQV, reflecting growing interest in the stock.
• IQVIA reported better-than-expected quarterly earnings of $2.81 per share, surpassing analyst estimates and resulting in a year-over-year revenue increase of 5.3% at $4.02 billion.

GDS Wealth Management raised its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,471 shares of the medical research company's stock after purchasing an additional 6,942 shares during the period. GDS Wealth Management's holdings in IQVIA were worth $11,719,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. EntryPoint Capital LLC grew its stake in IQVIA by 26.7% in the 1st quarter. EntryPoint Capital LLC now owns 1,778 shares of the medical research company's stock worth $313,000 after acquiring an additional 375 shares during the period. Fuller & Thaler Asset Management Inc. raised its holdings in shares of IQVIA by 29.8% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 6,179 shares of the medical research company's stock worth $1,089,000 after purchasing an additional 1,420 shares during the period. Wellington Management Group LLP raised its holdings in IQVIA by 232.4% in the first quarter. Wellington Management Group LLP now owns 32,542 shares of the medical research company's stock valued at $5,737,000 after buying an additional 22,751 shares during the period. Algert Global LLC acquired a new position in IQVIA during the first quarter valued at approximately $443,000. Finally, Philadelphia Trust Co. lifted its holdings in shares of IQVIA by 4.2% during the 1st quarter. Philadelphia Trust Co. now owns 113,275 shares of the medical research company's stock valued at $19,970,000 after acquiring an additional 4,603 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Down 1.7%

NYSE:IQV traded down $3.25 during mid-day trading on Monday, reaching $187.90. The stock had a trading volume of 318,380 shares, compared to its average volume of 1,954,690. The company has a market capitalization of $31.94 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 2.10 and a beta of 1.30. The stock's 50 day simple moving average is $173.70 and its two-hundred day simple moving average is $167.96. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the company earned $2.64 earnings per share. The firm's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Barclays upped their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Mizuho lifted their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Truist Financial boosted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.